Literature DB >> 16427663

Effects of ketamine on acute somatic nociception in wild-type and N-methyl-D-aspartate (NMDA) receptor epsilon1 subunit knockout mice.

Andrey B Petrenko1, Tomohiro Yamakura, Ahmed R Askalany, Tatsuro Kohno, Kenji Sakimura, Hiroshi Baba.   

Abstract

Although the properties of ketamine appear to be well characterized, there is a lot of ambiguity in the literature regarding its analgesic effects. After careful selection of proper experimental conditions and drug doses, we systematically characterized the effects of systemic ketamine on acute somatic nociception in mice and examined the role of the NMDA receptor epsilon1 subunit in mediating its analgesia. Intraperitoneal administration of ketamine was not analgesic in any of the phasic pain assays (thermal, mechanical, electrical) applied to C57BL/6 (wild-type) and NMDA receptor epsilon1 subunit knockout (mutant) mice. Surprisingly, rather than being analgesic for thermal nociception, ketamine showed pronociceptive properties in case of low-intensity heat stimulation in wild-type mice. In the formalin test (tonic pain), ketamine significantly reduced phase 2 nociceptive behavior in both wild-type and mutant mice. These data indicate that in wild-type mice ketamine has no analgesic effect on phasic pain in normal somatic tissues, but alleviates tonic pain after inflammation. Such analgesic spectrum of ketamine can be fully explained by its NMDA receptor antagonist properties. The results for the mutant mice suggest that the epsilon1 subunit of the NMDA receptor does not mediate the analgesic effects of ketamine in tonic pain.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16427663     DOI: 10.1016/j.neuropharm.2005.11.019

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  8 in total

1.  Atipamezole reverses ketamine-dexmedetomidine anesthesia without altering the antinociceptive effects of butorphanol and buprenorphine in female C57BL/6J mice.

Authors:  Jenelle M Izer; Tiffany L Whitcomb; Ronald P Wilson
Journal:  J Am Assoc Lab Anim Sci       Date:  2014-11       Impact factor: 1.232

2.  The absolute bioavailability of racemic ketamine from a novel sublingual formulation.

Authors:  Paul Rolan; Stephen Lim; Vivian Sunderland; Yandi Liu; Valeria Molnar
Journal:  Br J Clin Pharmacol       Date:  2014-06       Impact factor: 4.335

3.  HCN1 channel subunits are a molecular substrate for hypnotic actions of ketamine.

Authors:  Xiangdong Chen; Shaofang Shu; Douglas A Bayliss
Journal:  J Neurosci       Date:  2009-01-21       Impact factor: 6.167

Review 4.  Ketamine in the Past, Present, and Future: Mechanisms, Metabolites, and Toxicity.

Authors:  Eric S Schwenk; Basant Pradhan; Rohit Nalamasu; Lucas Stolle; Irving W Wainer; Michael Cirullo; Alexander Olsen; Joseph V Pergolizzi; Marc C Torjman; Eugene R Viscusi
Journal:  Curr Pain Headache Rep       Date:  2021-07-16

5.  CaMKII binding to GluN2B at S1303 has no role in acute or inflammatory pain.

Authors:  Uche P Maduka; Stephanie R White; Mei-Ling A Joiner; Johannes W Hell; Donna L Hammond
Journal:  Brain Res       Date:  2020-10-14       Impact factor: 3.252

6.  No evidence for the development of acute analgesic tolerance during and hyperalgesia after prolonged remifentanil administration in mice.

Authors:  Hideaki Ishii; Andrey B Petrenko; Tatsuro Kohno; Hiroshi Baba
Journal:  Mol Pain       Date:  2013-03-07       Impact factor: 3.395

7.  Recombinant neural progenitor transplants in the spinal dorsal horn alleviate chronic central neuropathic pain.

Authors:  Stanislava Jergova; Shyam Gajavelli; Nirmal Pathak; Jacqueline Sagen
Journal:  Pain       Date:  2016-04       Impact factor: 7.926

8.  Effects of midazolam, pentobarbital and ketamine on the mRNA expression of ion channels in a model organism Daphnia pulex.

Authors:  Changhong Dong; Anmin Hu; Yang Ni; Yunxia Zuo; Guo Hua Li
Journal:  BMC Anesthesiol       Date:  2013-10-18       Impact factor: 2.217

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.